Issue Date: November 19, 2007
Lead Therapeutics Draws Investors
San Francisco Bay Area-based Lead Therapeutics, a small-molecule drug discovery firm that plans to conduct most of its research in China, has raised $17 million from a group of private equity investors including Pappas Ventures, ProQuest Investments, and Mustang Ventures. Also putting money into Lead is China Gateway Life Science, the investment arm of the Chinese contract research firm ShangPharma. As part of the deal, Lead will start a research collaboration with ShangPharma's Shanghai ChemPartner subsidiary.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society